TechLab — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

TechLab is a long-established, privately held diagnostics company specializing in niche, high-value tests for gastrointestinal and respiratory infections. Its commercial portfolio is built around key products like the C. DIFF QUIK CHEK COMPLETE and LEUKO EZ VUE, which offer rapid, algorithm-based testing to improve laboratory efficiency. Beyond its own products, the company leverages its expertise in anaerobic culture and assay development through a profitable contract research and manufacturing (CDMO) business, serving a global customer base.

Infectious DiseaseGastroenterology

Technology Platform

Immunodiagnostic assay development (lateral flow, ELISA) for antigen and biomarker detection, with specialized expertise in anaerobic bacterial culture and analysis.

Opportunities

Growing global prevalence of C.

difficile and Inflammatory Bowel Disease (IBD) drives demand for its core tests.

The trend towards lab automation and efficiency favors its rapid, algorithm-based assays.

Its specialized contract research services are positioned to capitalize on outsourced R&D in gut microbiome and antimicrobial resistance studies.

Risk Factors

Revenue is concentrated in niche diagnostic areas, particularly C.

difficile testing, making it vulnerable to technological displacement or intense competition from larger diagnostics firms.

The business is subject to ongoing regulatory and reimbursement pressures inherent to the medical device industry.

Growth may be limited by its focused market segment and private company resources.

Competitive Landscape

TechLab competes in specialized segments against larger, diversified IVD companies like Abbott, Roche, and bioMérieux, which offer broad infectious disease panels. In fecal biomarkers, it competes with companies promoting calprotectin tests. Its key advantage is deep, focused expertise in enteric diseases and anaerobic bacteriology, which allows for differentiated products like its complete C. diff algorithm and stable lactoferrin assays.

More companies in United States →